Biotech company Oxford BioDynamics Plc, has announced its final results for the year ended 30 September 2020. Revenues dropped to £0.5 million (down from £0.9 million the previous year), and operating losses grew to £5 million from £3.7 million in 2019.
However, the company developed a Covid-19 severity test in under six months and Oxford BioDynamics is launching this, its first proprietary test, into the US market this year.
"As we announced during the year, our R&D project revenues were affected by the COVID-19 pandemic, but we were pleased to continue working with several partners throughout the year and to plan for the expansion of our strategic focus, which we announced in December.
"We developed a pipeline of molecular diagnostic tests developed using our EpiSwitch™ technology platform, ready to be deployed behind it. We look forward to sharing more progress over the rest of the year."
The newest episode of The Business Magazine Property Podcast, hosted by Stephen Emerson - Managing…
Ahead of the general election on 4 July, Saffery, the accounting and business advisory firm…
Gloucester Docks eatery Dr Foster is set to reopen on Friday 12 July as a…
Poole-based Greendale Construction has finished a contract to turn a dilapidated building into a luxury…
HR People Support, a Cheltenham-based provider of outsourced HR services, is celebrating its fifth anniversary.…
The positive impact of supporting startup businesses on the economy has been highlighted at an…